Assets

FAP-2286 targets the fibroblast activation protein (FAP), a molecule that is expressed in large amounts on the surface of cancer-associated fibroblasts (CAFs), which play a major role in the growth and progression of epithelial cancers. Since more than 90% of all epithelial tumors contain FAP-expressing CAFs, FAP is a genuine pan-tumor target and allows the treatment of a variety of cancer indications such as breast, colorectal, pancreatic and lung cancer as well as rarer indications such as sarcomas. Novartis has acquired exclusive global rights to 3BP’s FAP-targeting peptide technology. 3BP retained rights to certain imaging agents and FAP small molecules. The Phase 1/2 LuMIERE study of ¹⁷⁷Lu-FAP-2286 and ⁶⁸Ga-FAP-2286 (NCT04939610) is enrolling.

3BP-227 / FPI-2059 / IPN01087 is targeting the neurotensin receptor 1 (NTR1) which is highly expressed on the cancer cells of ductal pancreatic adenocarcinoma and several other tumor entities. The program is partnered with Fusion Pharmaceuticals globally. Using a theranostic approach, ²²⁵Ac-FPI-2059 is currently in preclinical development for treatment of solid tumors expressing NTSR1. Previously, the program was partnered with IPSEN Pharma SAS who sponsored a phase I/II trial with ¹⁷⁷Lu-FPI-2059 in patients with pancreatic adenocarcinoma, colorectal cancer and other solid tumors (NCT03525392).

3BP-4961 targets fibroblast activation protein (FAP) and can be labeled with ^99mTc for SPECT imaging of FAP expression. It has the potential to detect the majority of solid tumors and a variety of benign conditions similar to FDG, and could be used to image both malignant and benign disease using SPECT where PET imaging is not sufficiently available or accessible. 3BP-4961 will be available as a cold kit and will enter FIH imaging trials in 2023.

3BP-5201 targets fibroblast activation protein (FAP) and can be labeled with ⁶⁸Ga and ¹⁸F for PET imaging of FAP expression. It has the potential to detect the majority of solid tumors and a variety of benign conditions similar to FDG, and could be used to image both malignant and benign disease. 3BP-5201 will enter FIH imaging trials in 2023.

3BP-3775 is our development candidate binding to the GIP receptor (Glucose-dependent Insulinotropic Polypeptide receptor), which is highly expressed in a subset of neuroendocrine tumors (NETs). Since not all NETs can be treated with the currently available somatostatin receptor (sstr)-targeted radiopharmaceuticals such as Lutathera®, we aim to provide an alternative radiopharmaceutical treatment for sstr-negative and Lutathera®-ineligible patients. The GIP receptor program is developed by 3BP and will enter clinical development in 2022.

3BP-4452 / DPI-4452 / Debio 0228 targets carbonic anhydrase IX (CAIX) which is constitutively expressed in clear cell renal cell carcinoma and mesothelioma. In addition, CAIX is expressed in tumors of several different indications in areas that lack oxygen in an effort of the tumor to survive under low oxygen conditions. The program is partnered with Debiopharm International SA who has acquired exclusive worldwide rights to the program. A study to assess safety, tolerability and imaging characteristics of ⁶⁸Ga-DPI-4452 and to assess safety, tolerability, and efficacy of ¹⁷⁷Lu-DPI-4452 in participants with unresectable locally advanced or metastatic solid tumors is enrolling (NCT05706129).

3BP-6146 targets urokinase-type plasminogen activator receptor (uPAR) which is highly expressed in breast and brain cancer, among other indications. Thus, targeting uPAR could expand the list of oncology indications that may be treated using a radiopharmaceutical theranostic approach. The uPAR program is developed by 3BP and will enter FIH imaging trials in 2023.

3BP-6121 targets P-Cadherin which is highly expressed in breast, ovarian and colorectal cancer. This program may therefore expand the list of oncology indications that may be treated using a radiopharmaceutical theranostic approach. The P-Cadherin program is developed by 3BP and will enter FIH imaging trials in 2023.